In Vitro and In Vivo Evaluation of Fluorescently Labeled Borocaptate-Containing Liposomes
- PDF / 2,438,019 Bytes
- 11 Pages / 595.276 x 790.866 pts Page_size
- 79 Downloads / 182 Views
ORIGINAL ARTICLE
In Vitro and In Vivo Evaluation of Fluorescently Labeled Borocaptate-Containing Liposomes Vladimir Kanygin 1 & Alexander Zaboronok 1,2,3 & Iuliia Taskaeva 4,5,6 & Evgenii Zavjalov 1,7 & Rinat Mukhamadiyarov 1,8 & Aleksandr Kichigin 1 & Anna Kasatova 1,6 & Ivan Razumov 1,7 & Roman Sibirtsev 1 & Bryan J. Mathis 2 Received: 16 August 2020 / Accepted: 14 October 2020 # Springer Science+Business Media, LLC, part of Springer Nature 2020
Abstract Boron neutron capture therapy (BNCT), a binary cancer therapeutic modality, has moved to a new phase since development of accelerator-based neutron sources and establishment of BNCT centers in Finland and Japan. That stimulated efforts for better boron delivery agent development. As liposomes have shown effective boron delivery properties and sufficient tumor retention, fluorescent liposome labelling may serve as a rapid method to study initial ability of newly synthesized liposomes to be captured by tumor cells prior to experiments on boron accumulation and neutron irradiation. In this work, we studied the accumulation and biodistribution of pegylated liposomes with encapsulated borocaptate (BSH) and a fluorescent label (Nile Red) in U87 (human glioblastoma), SW-620 (human colon carcinoma), SK-MEL-28 (human melanoma), FetMSC (mesenchymal human embryo stem cells), and EMBR (primary embryocytes) cell lines as well as an orthotopic xenograft model of U87 glioma in SCID mice. Results indicate that fluorescent microscopy is effective at determining the intracellular localization of the liposomes using a fluorescent label. The synthesized, pegylated liposomes showed higher accumulation in tumors compared to normal cells, with characteristic concentration peaks in SW-620 and U87 cell lines, and provided in vivo tumor selectivity with several-fold higher tumor tissue fluorescence at the 6-h timepoint. Keywords BNCT . Drug delivery . Liposomes . Fluorescence . Borocaptate
Introduction Boron neutron capture therapy (BNCT) is a cancer treatment modality based on a boron-10 (10B)-containing compound
which is injected into the patient to selectively accumulate in tumor tissue, and a neutron source (a nuclear reactor or an accelerator) that generates epithermal neutrons to irradiate the tumor area. Here, neutron capture by 10B atoms takes
Electronic supplementary material The online version of this article (https://doi.org/10.1007/s10895-020-02637-5) contains supplementary material, which is available to authorized users. * Alexander Zaboronok [email protected] 1
Laboratory of Medical and Biological Problems of BNCT, Novosibirsk State University, Novosibirsk, Russian Federation
2
Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan
3
Department of Neurosurgery, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki 305-8575, Japan
4
Laboratory of Ultrastructural Research, Research Institute of Clinical and Experimental Lymphology – Branch of the Institute of Cytology and Genetics SB RAS, Novosibirsk, Russian Federation
5
Laboratory of
Data Loading...
